Innovita Biological Technology (688253)2025-01-23 09:55Financial Projections - The company expects to achieve an annual operating revenue of approximately RMB 621.34 million for 2024, representing a year-on-year growth of about 29.98%[3] - The projected net profit attributable to shareholders for 2024 is approximately RMB 245.70 million, reflecting a year-on-year increase of about 41.25%[3] - In 2023, the company reported an operating revenue of RMB 478.02 million and a net profit of RMB 173.95 million[5] Market Development - The growth in performance is attributed to the ongoing development of the national hierarchical medical system and increased awareness of early diagnosis and treatment among patients[6] - The company is actively expanding its market presence in both tiered hospitals and grassroots medical markets[6] Financial Data Disclaimer - The financial data provided in the forecast has not been audited by a registered accountant[4] - Investors are advised that the forecast data is preliminary and the final figures will be disclosed in the official 2024 annual report[8] - The company emphasizes the importance of recognizing investment risks associated with the preliminary financial data[8]